Exome Asset Management 13F annual report

Exome Asset Management is an investment fund managing more than $115 billion ran by Brianne Shergill. There are currently 50 companies in Mrs. Shergill’s portfolio. The largest investments include Eli Lilly & Co and Merus N.V, together worth $15.6 billion.

Limited to 30 biggest holdings

$115 billion Assets Under Management (AUM)

As of 7th August 2024, Exome Asset Management’s top holding is 9,700 shares of Eli Lilly & Co currently worth over $8.78 billion and making up 7.6% of the portfolio value. In addition, the fund holds 74,000 shares of Merus N.V worth $6.79 billion, whose value grew 21.5% in the past six months. The third-largest holding is Sarepta Therapeutics Inc worth $5.2 billion and the next is TG Therapeutics Inc worth $4.48 billion, with 251,600 shares owned.

Currently, Exome Asset Management's portfolio is worth at least $115 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Exome Asset Management

The Exome Asset Management office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Brianne Shergill serves as the Chief Compliance Officer at Exome Asset Management.

Recent trades

In the most recent 13F filing, Exome Asset Management revealed that it had opened a new position in Merus N.V and bought 74,000 shares worth $6.79 billion. This means they effectively own approximately 0.1% of the company. Merus N.V makes up 8.2% of the fund's Health Care sector allocation and has grown its share price by 120.9% in the past year.

The investment fund also strengthened its position in TG Therapeutics Inc by buying 21,300 additional shares. This makes their stake in TG Therapeutics Inc total 251,600 shares worth $4.48 billion. TG Therapeutics Inc soared 91.3% in the past year.

On the other hand, there are companies that Exome Asset Management is getting rid of from its portfolio. Exome Asset Management closed its position in BeiGene Ltd on 14th August 2024. It sold the previously owned 36,800 shares for $5.76 billion. Brianne Shergill also disclosed a decreased stake in Cigna by 0.2%. This leaves the value of the investment at $4.03 billion and 12,200 shares.

One of the smallest hedge funds

The two most similar investment funds to Exome Asset Management are Tenzing Global Management and M3 Advisory. They manage $115 billion and $115 billion respectively.


Brianne Shergill investment strategy

Exome Asset Management’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 72.3% of the total portfolio value. The fund focuses on investments in the United States as 52.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up 10% of the total holdings value. On the other hand, small-cap stocks make up only 6.0% of the portfolio. The average market cap of the portfolio companies is close to $12.7 billion.

The complete list of Exome Asset Management trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
Eli Lilly & Co
No change
9,700
$8,782,186,000 7.65%
Merus N.V
Opened
74,000
$6,791,730,000 5.91%
BeiGene Ltd
Closed
36,800
$5,755,152,000
Sarepta Therapeutics Inc
Opened
32,900
$5,198,200,000 4.53%
Alpine Immune Sciences Inc
Closed
117,000
$4,637,880,000
TG Therapeutics Inc
9.25%
251,600
$4,475,964,000 3.90%
Wave Life Sciences Ltd.
Opened
496,635
$4,406,264,000 3.84%
Cigna Group (The)
20.26%
12,200
$4,032,954,000 3.51%
Corbus Pharmaceuticals Hldgs
3.48%
84,790
$3,836,748,000 3.34%
Insmed Inc
20.78%
56,800
$3,805,600,000 3.31%
AMGEN Inc.
Opened
11,800
$3,686,910,000 3.21%
Travere Therapeutics Inc
22.32%
443,379
$3,644,576,000 3.17%
Avidity Biosciences, Inc.
Closed
135,169
$3,449,513,000
Madrigal Pharmaceuticals Inc
36.71%
10,800
$3,025,728,000 2.63%
Celldex Therapeutics Inc.
Closed
71,100
$2,984,067,000
Avadel Pharmaceuticals plc
Opened
209,092
$2,939,834,000 2.56%
Dexcom Inc
4.43%
25,928
$2,939,716,000 2.56%
Geron Corp.
Closed
886,800
$2,926,440,000
Autolus Therapeutics plc
Opened
839,472
$2,921,362,000 2.54%
Aerovate Therapeutics Inc
Closed
98,485
$2,912,201,000
Intuitive Surgical Inc
No change
6,358
$2,828,356,000 2.46%
Morphosys AG
Closed
154,800
$2,808,072,000
Dr Reddys Labs Ltd
57.79%
36,300
$2,765,698,000 2.41%
Disc Medicine Inc
Opened
61,000
$2,749,270,000 2.39%
Ascendis Pharma A/S
Opened
20,000
$2,727,600,000 2.37%
Kura Oncology Inc
Opened
131,742
$2,712,568,000 2.36%
Krystal Biotech Inc
Closed
14,700
$2,615,571,000
Biohaven Ltd
Opened
90,189
$2,539,684,000 2.21%
Masimo Corp
Opened
19,800
$2,493,612,000 2.17%
Centessa Pharmaceuticals Plc
No change
274,900
$2,482,348,000 2.16%
Tarsus Pharmaceuticals, Inc.
Closed
66,300
$2,410,005,000
Guardant Health Inc
No change
79,000
$2,281,520,000 1.99%
Cabaletta Bio Inc
Opened
300,200
$2,245,496,000 1.96%
Arvinas Inc
Opened
82,400
$2,193,488,000 1.91%
Inozyme Pharma, Inc.
Closed
273,413
$2,094,344,000
Natera Inc
No change
18,650
$2,019,608,000 1.76%
BridgeBio Pharma Inc
61.67%
78,907
$1,998,714,000 1.74%
Rhythm Pharmaceuticals Inc.
Closed
45,603
$1,975,978,000
Fulcrum Therapeutics Inc
Opened
302,700
$1,876,740,000 1.63%
Exact Sciences Corp.
Closed
26,700
$1,843,902,000
Cytokinetics Inc
Closed
26,008
$1,823,421,000
Apellis Pharmaceuticals Inc
Opened
46,900
$1,799,084,000 1.57%
Regenxbio Inc
Closed
84,470
$1,779,783,000
Biogen Inc
Closed
8,200
$1,768,166,000
Ocular Therapeutix Inc
Closed
193,600
$1,761,760,000
Agios Pharmaceuticals Inc
Closed
59,902
$1,751,534,000
Alphatec Holdings Inc
Opened
162,100
$1,693,946,000 1.47%
Penumbra Inc
Closed
7,353
$1,641,043,000
Olema Pharmaceuticals, Inc.
Closed
143,400
$1,623,288,000
Establishment Labs Holdings Inc
Opened
26,000
$1,599,530,000 1.39%
Arrowhead Pharmaceuticals In
Closed
55,700
$1,593,020,000
AbCellera Biologics Inc.
Opened
514,900
$1,524,104,000 1.33%
Zai Lab Ltd
32.77%
86,700
$1,502,510,000 1.31%
Terns Pharmaceuticals Inc
Closed
227,821
$1,494,506,000
Marinus Pharmaceuticals Inc
Closed
163,100
$1,474,424,000
Inari Med Inc
Closed
30,100
$1,444,198,000
Intra-Cellular Therapies Inc
Closed
20,300
$1,404,760,000
Pliant Therapeutics, Inc.
Opened
124,000
$1,333,000,000 1.16%
Shockwave Med Inc
Closed
4,000
$1,302,520,000
Rezolute Inc
Opened
282,400
$1,214,320,000 1.06%
Alvotech
Opened
99,000
$1,203,840,000 1.05%
Regulus Therapeutics Inc
Closed
402,504
$1,159,212,000
Gossamer Bio, Inc.
Opened
1,127,699
$1,015,944,000 0.88%
Enliven Therapeutics Inc
Closed
57,635
$1,013,800,000
Elevation Oncology Inc
No change
369,322
$997,170,000 0.87%
Ventyx Biosciences Inc
Closed
163,922
$901,571,000
Procaps Group Sa
Opened
129,301
$877,428,000 0.76%
Ultragenyx Pharmaceutical In
Closed
17,800
$831,082,000
Syros Pharmaceuticals Inc.
Opened
159,175
$821,344,000 0.72%
Quanterix Corp
No change
59,650
$787,976,000 0.69%
Q32 Bio Inc
32.54%
43,865
$787,376,000 0.69%
VYNE Therapeutics Inc.
14.92%
353,434
$696,264,000 0.61%
Pmv Pharmaceuticals Inc
Opened
358,400
$580,608,000 0.51%
Aprea Therapeutics, Inc.
Opened
137,174
$558,298,000 0.49%
Adagene Inc
2.90%
150,876
$461,832,000 0.40%
I-Mab
16.69%
271,400
$453,238,000 0.39%
Hillevax Inc
Opened
18,000
$260,280,000 0.23%
Sagimet Biosciences Inc
16.75%
50,700
$173,394,000 0.15%
Pacific Biosciences Calif In
No change
75,300
$103,162,000 0.09%
AvroBio Inc
Closed
61,135
$78,253,000
No transactions found
Showing first 500 out of 80 holdings